On Jun 29, 2018 Viking Therapeutics (NASDAQ:VKTX) with $15 Target Was Coveraged By Raymond James.

June 29, 2018 - By Clara Lewis

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

What Price Target Has Raymond James Given Viking Therapeutics (NASDAQ:VKTX)

New York: On Thursday morning, Viking Therapeutics (NASDAQ:VKTX) coverage was initiated with a Outperform rating and $15 TP at Raymond James. That’s upside potential of 57.40 % from company’s last close price.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

A total of 5 analysts rate Viking Therapeutics (NASDAQ:VKTX) as follows: 5 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:VKTX) has 6 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Monday, March 26 the firm has “Buy” rating given by H.C. Wainwright. On Friday, June 1 the firm earned “Buy” rating by Maxim Group. On Thursday, March 8 the stock has “Buy” rating by Roth Capital. The stock rating was maintained by H.C. Wainwright with “Buy” on Friday, June 1.

Ticker’s shares touched $9.5343 during the last trading session after 2.51% change.Currently Viking Therapeutics, Inc. is uptrending after 320.16% change in last June 29, 2017. VKTX has also 1.31M shares volume. The stock outperformed the S&P 500 by 307.59%.

Earnings report for Viking Therapeutics, Inc. (NASDAQ:VKTX) is awaited on August, 8., as reported by RTT. EPS of $-0.12 is 42.86 % up from 2017’s $-0.21 EPS. 20.00 % negative EPS growth is what analysts predict. $-0.10 EPS was published for last quarter.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.The company has $567.85 million market cap. The Company’s lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.Currently it has negative earnings. The firm is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news posted briefly go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Seekingalpha.com. The titles are as follows: “Viking Therapeutics, Buy the Dip?” posted on June 26, 2018, “Viking Therapeutics: What Now After ‘Yuge’ Rally?” on June 12, 2018, “Viking Therapeutics completes enrollment in Phase 2 study of VK2809” with a publish date: June 05, 2018, “3 Growth Stocks at Deep-Value Prices” and the last “Viking Therapeutics: Sell The Pop On The Sympathy Play” with publication date: June 01, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.